Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Author Profile

Adaani Frost

Professor of Medicine
Baylor College of Medicine
Director, Pulmonary Hypertension Service
Methodist Hospital
Houston, Texas

Journal Articles

  • Navigating the Road to Transplant in Pulmonary Arterial Hypertension: A Road Less Taken Dramatic advances in therapy for pulmonary arterial hypertension (PAH) in the last 20 years have improved survival from a median of 2.5 years in the pretreatment era to 7.5 years currently. However, impressive as that may seem, it is important to note that a median survival of 7.5 years is equivalent to that of surgically resected non-small cell lung cancer, thus underscoring the importance of lung transplantation as a treatment option in patients with PAH. In this edition of Advances, Edelman has reviewed the pathway to transplantation for patients with PAH, detailing the recommendations for timing of referral, listing for lung transplantation, the role of the lung allocation score in allocating a donor organ, and the outcome of lung transplantation.
  • Pulmonary Arterial Hypertension: Therapeutic Considerations Editor-in-Chief Victor Tapson, MD, interviewed a select panel of experts in pulmonary hypertension to obtain their review and comments on the new evidence-based clinical practice guidelines of the American College of Chest Physicians.
  • Pulmonary Hypertension and Lung Transplantation, 2010